Telmisartan Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Description
Telmisartan Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
The global telmisartan market size reached US$ 3.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 3.0% during 2022-2028.
Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.
Telmisartan Market Trends:
Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global telmisartan market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on indication and distribution channel.
Breakup by Indication:
Hypertension
Cardiovascular Risk Reduction
Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.
Key Questions Answered in This Report:
How has the global telmisartan market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global telmisartan market?
What are the key regional markets?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global telmisartan market and who are the key players?
What is the degree of competition in the industry?
Table of Contents
138 Pages
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Telmisartan Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Indication
- 6.1 Hypertension
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Cardiovascular Risk Reduction
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 7 Market Breakup by Distribution Channel
- 7.1 Hospital Pharmacies
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Drug Stores and Retail Pharmacies
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Online Stores
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
- 9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
- 10 Value Chain Analysis
- 11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
- 12 Price Analysis
- 13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Aurobindo Pharma USA
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.3 Boehringer Ingelheim International GmbH
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Cipla Limited
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Hikma Pharmaceuticals plc
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Jubilant Cadista Pharmaceutical
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 Sanofi S.A.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.)
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.9 Torrent Pharmaceuticals Ltd
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
